Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 3/20 | 0.54 |
| ▸ | CDK2 | P24941 | 3/20 | 0.54 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.54 |
| ▸ | ROCK1 | Q13464 | 17/20 | 0.52 |
| ▸ | TTBK1 | Q5TCY1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13575038 | 0.87 | ROCK1 (0.52) | CDC7CDK2ROCK1TTBK1 | |
| SCHEMBL12743487 | 0.84 | ROCK1 (0.47) | CDC7CDK2ROCK1TTBK1 | |
| SCHEMBL1613473 | 0.79 | CDC7 (0.64) | CDC7CDK2MAP3K14ROCK1TTBK1 | |
| SCHEMBL1613992 | 0.77 | PAK4 (0.46) | CDC7CDK2MAP3K14ROCK1TTBK1 | |
| SCHEMBL1612241 | 0.76 | CDC7 (0.63) | CDC7CDK2MAP3K14ROCK1TTBK1 | |
| SCHEMBL1613399 | 0.72 | CDC7 (0.57) | CDC7CDK2MAP3K14ROCK1TTBK1 | |
| SCHEMBL24153582 | 0.71 | CDC7 (1.00) | CDC7CDK2MAP3K14ROCK1 | |
| SCHEMBL24152590 | 0.70 | CDC7 (0.51) | CDC7CDK2MAP3K14ROCK1 | |
| SCHEMBL31618794 | 0.69 | CDC7 (0.56) | CDC7CDK2MAP3K14ROCK1 | |
| SCHEMBL12821427 | 0.68 | ROCK1 (1.00) | ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2315751-A1 | ALKYNYL ALCOHOLS AS KINASE INHIBITORS | Amgen Inc. (US) | 2011-05-04 | — | — | EP | disclosed |
| US-20110086834-A1 | ALKYNYL ALCOHOLS AS KINASE INHIBITORS | AMGEN INC. (US) | 2011-04-14 | — | — | US | disclosed |
| US-20110086834-A1 | ALKYNYL ALCOHOLS AS KINASE INHIBITORS | AMGEN INC. (US) | 2011-04-14 | — | — | US | disclosed |
| US-20110086834-A1 | ALKYNYL ALCOHOLS AS KINASE INHIBITORS | AMGEN INC. (US) | 2011-04-14 | — | — | US | disclosed |
| WO-2009158011-A1 | ALKYNYL ALCOHOLS AS KINASE INHIBITORS | AMGEN INC. (US) | 2009-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110086834-A1 | ALKYNYL ALCOHOLS AS KINASE INHIBITORS | NFKBIA, MAP3K1, MAP3K2 | CDC7 1006/4885CDK2 1037/4885MAP3K14 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.